Alnylam Pharmaceuticals, Inc. reported a total revenue of $594.2 million for the first quarter of 2025, marking a 20% increase from $494.3 million in the same period of 2024. The growth was primarily driven by a 28% rise in net product revenues, which reached $468.5 million, up from $365.2 million year-over-year. This increase was largely attributed to strong sales of AMVUTTRA, which saw a 59% increase in revenue, while ONPATTRO experienced a decline of 29% due to patient transitions to AMVUTTRA. The company reported a net loss of $57.5 million, a slight improvement from a loss of $65.9 million in the prior year.
In terms of operational developments, Alnylam's product portfolio includes six marketed products, with AMVUTTRA recently receiving FDA approval for treating cardiomyopathy associated with ATTR amyloidosis. The company also announced a strategic collaboration with Roche for the development of zilebesiran, which has the potential to generate significant milestone payments and royalties. As of March 31, 2025, Alnylam had 130,388,393 shares of common stock outstanding, reflecting a modest increase from the previous quarter.
The company’s financial position remains strong, with cash and cash equivalents totaling $1.02 billion, up from $966.4 million at the end of 2024. Alnylam's total assets were reported at $4.21 billion, while total liabilities decreased to $4.10 billion from $4.17 billion. The company continues to invest heavily in research and development, with R&D expenses amounting to $265.1 million, a slight increase from $261.0 million in the prior year. Selling, general, and administrative expenses also rose to $239.9 million, reflecting ongoing investments in commercial infrastructure.
Looking ahead, Alnylam aims to achieve sustainable operating profitability by the end of 2025, supported by its Alnylam P5x25 strategy, which focuses on expanding its product offerings and enhancing its global commercial capabilities. The company anticipates continued growth in revenues from its existing products and collaborations, particularly as it advances its pipeline of investigational RNAi therapeutics. However, Alnylam acknowledges the inherent risks in drug development and the competitive landscape, which could impact its future financial performance.
About ALNYLAM PHARMACEUTICALS, INC.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.